Cardiovascular impact of drugs used in the treatment of diabetes

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metformin—mode of action and clinical implications for diabetes and cancer

(2014) Ida Pernicova et al.   Nature Reviews Endocrinology

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

(2013) Kenneth W. Mahaffey et al.   AMERICAN HEART JOURNAL

Clinical use of adiponectin as a marker of metabolic dysregulation

(2013) Kieren J. Mather et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1

(2013) Gnanapragasam Arunachalam et al.   BRITISH JOURNAL OF PHARMACOLOGY

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

(2013) Yuji Ishibashi et al.   Cardiovascular Diabetology

Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact

(2013) Frank Gieseler et al.   Cell Communication and Signaling

Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease

(2013) Huige Li et al.   CURRENT OPINION IN PHARMACOLOGY

Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk

(2013) Serena Del Turco et al.   CURRENT PHARMACEUTICAL DESIGN

Pioglitazone Acutely Reduces Energy Metabolism and Insulin Secretion in Rats

(2013) J. Lamontagne et al.   DIABETES

Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates

(2013) R. A. DeFronzo et al.   DIABETES

AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer

(2013) D. G. Hardie   DIABETES

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Molecular mechanism of action of metformin: old or new insights?

(2013) Graham Rena et al.   DIABETOLOGIA

The potential of novel biomarkers to improve risk prediction of type 2 diabetes

(2013) Christian Herder et al.   DIABETOLOGIA

Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients

(2013) Simona Bo et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes

(2013) Craig J. Currie et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin resistance in the vasculature

(2013) Kieren J. Mather et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of Folic Acid Supplementation on Homocysteine, Serum Total Antioxidant Capacity, and Malondialdehyde in Patients with Type 2 Diabetes Mellitus

(2013) Vahide Aghamohammadi et al.   JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

Endothelial Cells Actively Concentrate Insulin During its Transendothelial Transport

(2013) Amanda J. Genders et al.   MICROCIRCULATION

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

(2013) Russell A. Miller et al.   NATURE

Diabetes drugs ride a bumpy road

(2013) Heidi Ledford   NATURE

Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin

(2013) Morgan D Fullerton et al.   NATURE MEDICINE

Cardiovascular effects of gliptins

(2013) André J. Scheen   Nature Reviews Cardiology

Higher glucose levels associated with lower memory and reduced hippocampal microstructure

(2013) L. Kerti et al.   NEUROLOGY

Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus

(2013) Robert M. Guthrie   POSTGRADUATE MEDICINE

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

(2013) André J. Scheen   POSTGRADUATE MEDICINE

Metformin improves healthspan and lifespan in mice

(2013) Alejandro Martin-Montalvo et al.   Nature Communications

Metformin: an old but still the best treatment for type 2 diabetes

(2013) Lilian Beatriz Aguayo Rojas et al.   Diabetology & Metabolic Syndrome

Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients

(2013) Makoto Ayaori et al.   Journal of the American Heart Association

Intensive insulin for type 2 diabetes: the risk of causing harm

(2013) Christopher J Nolan et al.   Lancet Diabetes & Endocrinology

Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions

(2012) C. A. Bourg et al.   ANNALS OF PHARMACOTHERAPY

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease

(2012) Jixin Zhong et al.   ATHEROSCLEROSIS

The endothelium: influencing vascular smooth muscle in many ways

(2012) Chris R. Triggle et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

(2012) Swenja Kröller-Schön et al.   CARDIOVASCULAR RESEARCH

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis

(2012) K. M. Pantalone et al.   DIABETES OBESITY & METABOLISM

Endothelial Dysfunction in Diabetes Mellitus: Possible Involvement of Endoplasmic Reticulum Stress?

(2012) Basma Basha et al.   Experimental Diabetes Research

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice

(2012) Junichi Matsubara et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study

(2012) Ronac Mamtani et al.   JNCI-Journal of the National Cancer Institute

AMPK: a nutrient and energy sensor that maintains energy homeostasis

(2012) D. Grahame Hardie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences

(2012) Eunice Mah et al.   NUTRITION RESEARCH

Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus

(2012) Stephen A. Brunton   POSTGRADUATE MEDICINE

Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus

(2012) Samar Singh et al.   Current Cardiology Reports

Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways

(2011) Eugenio Cersosimo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Acute Exposure to Low Glucose Rapidly Induces Endothelial Dysfunction and Mitochondrial Oxidative Stress

(2011) Jingli Wang et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients

(2011) Paul A. J. Krijnen et al.   BASIC RESEARCH IN CARDIOLOGY

Impaired Insulin Signaling in Endothelial Cells Reduces Insulin-Induced Glucose Uptake by Skeletal Muscle

(2011) Tetsuya Kubota et al.   Cell Metabolism

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives

(2011) Dimitris Tousoulis et al.   Current Vascular Pharmacology

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

(2011) D. Lamers et al.   DIABETES

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes

(2011) P. C. M. van Poppel et al.   DIABETES CARE

Type 2 diabetes across generations: from pathophysiology to prevention and management

(2011) Christopher J Nolan et al.   LANCET

The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives

(2011) Lei Chen et al.   Nature Reviews Endocrinology

DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion

(2011) Hui-Chun Ku et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

(2011) Zubair Shah et al.   VASCULAR PHARMACOLOGY

Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1

(2011) Gian Paolo Fadini et al.   VASCULAR PHARMACOLOGY

Caveolin-1 is required for vascular endothelial insulin uptake

(2010) Hong Wang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

(2010) Hisko Oeseburg et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines

(2010) Wataru Takasawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation

(2010) Simon A. Hawley et al.   Cell Metabolism

Oxidative Stress and Diabetic Complications

(2010) Ferdinando Giacco et al.   CIRCULATION RESEARCH

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Novel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function: Clinical recommendations

(2010) A. Frid et al.   DIABETES CARE

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

(2010) D. J. Betteridge   DIABETIC MEDICINE

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

(2010) S. L. Bowker et al.   DIABETOLOGIA

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone

(2010) David J. Graham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

(2010) Marc Foretz et al.   JOURNAL OF CLINICAL INVESTIGATION

A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS

(2010) Chris R. Triggle et al.   Journal of the American Society of Hypertension

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

A role for mitochondria in NLRP3 inflammasome activation

(2010) Rongbin Zhou et al.   NATURE

Endothelial dysfunction in diabetes: multiple targets for treatment

(2010) Hong Ding et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

(2010) Jian Chen et al.   Diabetes Therapy

The impact of glucose-lowering therapy on cardiovascular outcomes

(2009) Eberhard Standl et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

(2009) Mozhgan Dorkhan et al.   Cardiovascular Diabetology

AMP-Activated Protein Kinase Functionally Phosphorylates Endothelial Nitric Oxide Synthase Ser633

(2009) Zhen Chen et al.   CIRCULATION RESEARCH

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Metformin - the gold standard in type 2 diabetes: what does the evidence tell us?

(2009) E. Bosi   DIABETES OBESITY & METABOLISM

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Carbutamide — The first oral antidiabetic

(2009) H. Kleinsorge   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

(2008) Brian D. Green et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Use of Thiazolidinediones and Fracture Risk

(2008) Christian Meier et al.   ARCHIVES OF INTERNAL MEDICINE

Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance

(2008) Markolf Hanefeld et al.   CARDIOVASCULAR DRUGS AND THERAPY

Insulin signalling in the heart

(2008) L. Bertrand et al.   CARDIOVASCULAR RESEARCH

Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies

(2008) A. D. Rao et al.   DIABETES CARE

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

(2008) Assam El-Osta et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS

Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more

(2007) R Ramachandran et al.   BRITISH JOURNAL OF PHARMACOLOGY